OliX Pharmaceuticals is the first clinical stage pharmaceutical company in Asia developing therapeutics based on the science of RNA interference (RNAi).

The Company’s core RNAi technology platform, asymmetric siRNA (asiRNA), represents the next generation of RNAi therapeutics that offer efficient gene regulation. Based on asiRNA technology, OliX has developed cell-penetrating asiRNA (cp-asiRNA) to target locally administrable diseases, such as hypertrophic scars, age-related macular degeneration (AMD), and hair loss. The Company’s third RNAi therapeutic platform, GalNAc-asiRNA, targets a variety of liver diseases.

OliX is currently developing RNAi therapeutics for eye diseases with Théa Open Innovation, a leading European ophthalmology company, and actively advancing pipeline programs for patients with HBV, NASH, and other prevalent diseases. The Company won the ‘Korea New Drug Award’ in 2021 and was certified as ‘Innovative pharmaceutical company’ in 2020.

With its proprietary technology, OliX will continue on its noble mission to contribute to the health and happiness of mankind and become one of the major nucleic acid therapeutics companies.

The global RNA therapeutics market has been rapidly growing, with more than 12 out-licensing deals of over $1 billion for the past five years.

OliX’s platform technology has great growth potential as it can secure various pipeline programs with reduced time.

The Company also has excellent in-house expertise spanning R&D, clinical development, and commercialization; as well as world-renowned experts as Scientific Advisory Board members.

Since its listing on the KOSDAQ in 2018, OliX has established a subsidiary in Boston, a biotech hub in the US. The Company continued expanding its network and R&D investment by establishing a chemistry lab in San Diego in 2019.

OliX is actively collaborating with global partners in various fields to accelerate drug development.

At OliX, there are numerous opportunities to grow into a global talent through working at overseas subsidiaries and cooperating with different partners.

At OliX, all HR–related decisions are made based on individual competency and performance.

Through a feedback-oriented evaluation system, each OliXer is strongly encouraged to improve their performance and competency. Regardless of the number of years of experience, a high evaluation rating could lead to a promotion anytime. OliX also provides industry-leading compensation, including incentives and/or stock options for those with outstanding performances.